CENTOGENE joins BCRQUEST Global Data Partner Network to increase access to data-driven genomic insights.

BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, has joined BCP’s Global Data Partner Network, BCRQUEST.com, to enable access to datasets for the acceleration and de-risking of target & drug discovery, as well as optimization of clinical pipelines.

Under the terms of the agreement, CENTOGENE and BC Platforms are entering a strategic partnership to make unique dataset including more than 80,000 Whole Exome and Whole Genome Sequences containing rare and neurodegenerative disease data more accessible.

The addition of these first CENTOGENE datasets represents an estimated 20% increase in both the breadth and depth of genomic data currently available via BC Platforms. The dataset reflect a diverse geographic and ethnic sample base and includes a large share of pediatric cases in rare and neurodegenerative diseases, with data modalities including clinical, multiomic, and socio-demographic data. This first dataset has been made available from the diverse CENTOGENE Biodatabank, which currently contains nearly 700,000 patients represented from over 120 countries, over 70% of whom are of non-European descent.

Tero Silvola, CEO of BC Platforms, said, “CENTOGENE is a unique partner as it brings a wealth of genomic sequencing data to our Global Data Partner Network. Such data is especially valuable in research for new and improved diagnostics and treatments. This fuels the ability of biotech companies to uncover highly specific patient and population insights to drive the health systems of the future, delivering patient benefit around the world.”

Kim Stratton, CEO of CENTOGENE, said, “For many diseases, especially in the fields of rare and neurodegenerative diseases where we specialise, there is a significant unmet medical need to truly unveil deeper data on the genetic factors to unlock insights to accelerate diagnosis and precision medicine. Through our partnership with BC Platforms, we want to advance global scientific research by providing secure access to a rich source of insights to accelerate data-driven, life-changing answers to patients around the world.”

About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and biopharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted biopharma drug discovery, development, and commercialization.

Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This diverse data is captured in our CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

By translating our data and expertise into tangible insights, we have supported over 50 collaborations with biopharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target & drug screening, clinical development, market access and expansion, as well as offering Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.

To discover more about our products, pipeline, and patient-driven purpose, visit www.centogene.com and follow us on LinkedIn.